Literature DB >> 20074952

The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability.

A M Glanzman1, E Mazzone, M Main, M Pelliccioni, J Wood, K J Swoboda, C Scott, M Pane, S Messina, E Bertini, E Mercuri, R S Finkel.   

Abstract

The motor skills of patients with spinal muscular atrophy, type I (SMA-I) are very limited. It is difficult to quantify the motor abilities of these patients and as a result there is currently no validated measure of motor function that can be utilized as an outcome measure in clinical trials of SMA-I. We have developed the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders ("CHOP INTEND") to evaluate the motor skills of patients with SMA-I. The test was developed following the evaluation of 26 infants with SMA-I mean age 11.5 months (1.4-37.9 months) with the Test of Infant Motor Performance and The Children's Hospital of Philadelphia Test of Strength in SMA, a newly devised motor assessment for SMA. Items for the CHOP INTEND were selected by an expert panel based on item mean and standard deviation, item frequency distribution, and Chronbach's alpha. Intra-rater reliability of the resulting test was established by test-retest of 9 infants with SMA-I over a 2 month period; Intraclass correlation coefficient (ICC) (3,1)=0.96. Interrater reliability was by video analysis of a mixed group of infants with neuromuscular disease by 4 evaluators; ICC (3,4)=0.98 and in a group of 8 typically developing infants by 5 evaluators ICC (3,5)=0.93. The face validity of the CHOP INTEND is supported by the use of an expert panel in item selection; however, further validation is needed. The CHOP INTEND is a reliable measure of motor skills in patients with SMA-I and neuromuscular disorders presenting in infancy. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20074952      PMCID: PMC3260046          DOI: 10.1016/j.nmd.2009.11.014

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  12 in total

1.  An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients.

Authors:  Jessica M O'Hagen; Allan M Glanzman; Michael P McDermott; Patricia A Ryan; Jean Flickinger; Janet Quigley; Susan Riley; Erica Sanborn; Carrie Irvine; William B Martens; Christine Annis; Rabi Tawil; Maryam Oskoui; Basil T Darras; Richard S Finkel; Darryl C De Vivo
Journal:  Neuromuscul Disord       Date:  2007-07-19       Impact factor: 4.296

2.  A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients.

Authors:  K Zerres; S Rudnik-Schöneborn; E Forrest; A Lusakowska; J Borkowska; I Hausmanowa-Petrusewicz
Journal:  J Neurol Sci       Date:  1997-02-27       Impact factor: 3.181

3.  A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

Authors:  U R Monani; C L Lorson; D W Parsons; T W Prior; E J Androphy; A H Burghes; J D McPherson
Journal:  Hum Mol Genet       Date:  1999-07       Impact factor: 6.150

4.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.

Authors:  Markus Feldkötter; Verena Schwarzer; Radu Wirth; Thomas F Wienker; Brunhilde Wirth
Journal:  Am J Hum Genet       Date:  2001-12-21       Impact factor: 11.025

Review 5.  Modern management of spinal muscular atrophy.

Authors:  Susan T Iannaccone
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

Review 6.  Spinal muscular atrophy: clinical classification and disease heterogeneity.

Authors:  Barry S Russman
Journal:  J Child Neurol       Date:  2007-08       Impact factor: 1.987

7.  Identification and characterization of a spinal muscular atrophy-determining gene.

Authors:  S Lefebvre; L Bürglen; S Reboullet; O Clermont; P Burlet; L Viollet; B Benichou; C Cruaud; P Millasseau; M Zeviani
Journal:  Cell       Date:  1995-01-13       Impact factor: 41.582

Review 8.  Therapeutics development for spinal muscular atrophy.

Authors:  Charlotte J Sumner
Journal:  NeuroRx       Date:  2006-04

9.  Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications.

Authors:  K Zerres; S Rudnik-Schöneborn
Journal:  Arch Neurol       Date:  1995-05

Review 10.  Drug treatment for spinal muscular atrophy type I.

Authors:  Wendy M J Bosboom; Alexander F J E Vrancken; Leonard H van den Berg; John H J Wokke; Susan T Iannaccone
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
View more
  61 in total

1.  Rasch analysis of clinical outcome measures in spinal muscular atrophy.

Authors:  Stefan J Cano; Anna Mayhew; Allan M Glanzman; Kristin J Krosschell; Kathryn J Swoboda; Marion Main; Birgit F Steffensen; Carole Bérard; Françoise Girardot; Christine A M Payan; Eugenio Mercuri; Elena Mazzone; Bakri Elsheikh; Julaine Florence; Linda S Hynan; Susan T Iannaccone; Leslie L Nelson; Shree Pandya; Michael Rose; Charles Scott; Reza Sadjadi; Mackensie A Yore; Cynthia Joyce; John T Kissel
Journal:  Muscle Nerve       Date:  2013-07-26       Impact factor: 3.217

2.  Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.

Authors:  Claudia D Wurster; Petra Steinacker; René Günther; Jan C Koch; Paul Lingor; Zeljko Uzelac; Simon Witzel; Kurt Wollinsky; Benedikt Winter; Alma Osmanovic; Olivia Schreiber-Katz; Rami Al Shweiki; Albert C Ludolph; Susanne Petri; Andreas Hermann; Markus Otto
Journal:  J Neurol       Date:  2019-09-24       Impact factor: 4.849

3.  c.835-5T>G Variant in SMN1 Gene Causes Transcript Exclusion of Exon 7 and Spinal Muscular Atrophy.

Authors:  Shuang Wu; Yun-Lu Li; Ning-Yi Cheng; Chong Wang; En-Lin Dong; Ying-Qian Lu; Jin-Jing Li; Xin-Xin Guo; Xiang Lin; Lu-Lu Lai; Zhi-Wei Liu; Ning Wang; Wan-Jin Chen
Journal:  J Mol Neurosci       Date:  2018-05-24       Impact factor: 3.444

Review 4.  Functional movement assessment with the Test of Infant Motor Performance.

Authors:  Suzann K Campbell
Journal:  J Perinatol       Date:  2021-04-21       Impact factor: 2.521

5.  Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.

Authors:  Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

6.  Natural history of infantile-onset spinal muscular atrophy.

Authors:  Stephen J Kolb; Christopher S Coffey; Jon W Yankey; Kristin Krosschell; W David Arnold; Seward B Rutkove; Kathryn J Swoboda; Sandra P Reyna; Ai Sakonju; Basil T Darras; Richard Shell; Nancy Kuntz; Diana Castro; Julie Parsons; Anne M Connolly; Claudia A Chiriboga; Craig McDonald; W Bryan Burnette; Klaus Werner; Mathula Thangarajh; Perry B Shieh; Erika Finanger; Merit E Cudkowicz; Michelle M McGovern; D Elizabeth McNeil; Richard Finkel; Susan T Iannaccone; Edward Kaye; Allison Kingsley; Samantha R Renusch; Vicki L McGovern; Xueqian Wang; Phillip G Zaworski; Thomas W Prior; Arthur H M Burghes; Amy Bartlett; John T Kissel
Journal:  Ann Neurol       Date:  2017-12-08       Impact factor: 10.422

Review 7.  Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy.

Authors:  Alessandra Govoni; Delia Gagliardi; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

8.  Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type I.

Authors:  Kristin J Krosschell; Jo Anne Maczulski; Charles Scott; Wendy King; Jill T Hartman; Laura E Case; Donata Viazzo-Trussell; Janine Wood; Carolyn A Roman; Eva Hecker; Marianne Meffert; Maude Léveillé; Krista Kienitz; Kathryn J Swoboda
Journal:  Pediatr Phys Ther       Date:  2013       Impact factor: 3.049

9.  Observational study of spinal muscular atrophy type I and implications for clinical trials.

Authors:  Richard S Finkel; Michael P McDermott; Petra Kaufmann; Basil T Darras; Wendy K Chung; Douglas M Sproule; Peter B Kang; A Reghan Foley; Michelle L Yang; William B Martens; Maryam Oskoui; Allan M Glanzman; Jean Flickinger; Jacqueline Montes; Sally Dunaway; Jessica O'Hagen; Janet Quigley; Susan Riley; Maryjane Benton; Patricia A Ryan; Megan Montgomery; Jonathan Marra; Clifton Gooch; Darryl C De Vivo
Journal:  Neurology       Date:  2014-07-30       Impact factor: 9.910

10.  An observational study of functional abilities in infants, children, and adults with type 1 SMA.

Authors:  Marika Pane; Concetta Palermo; Sonia Messina; Valeria A Sansone; Claudio Bruno; Michela Catteruccia; Maria Sframeli; Emilio Albamonte; Marina Pedemonte; Adele D'Amico; Giorgia Brigati; Roberto de Sanctis; Giorgia Coratti; Simona Lucibello; Enrico Bertini; Giuseppe Vita; Francesco Danilo Tiziano; Eugenio Mercuri
Journal:  Neurology       Date:  2018-07-25       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.